



UNITED Scientific Group

Exhibitor



III International conference on

CANCER RESEARCH AND TARGETED THERAPY

www.unitedscientificgroup.com/conferences/cancer-research-therapy/

CRT PROGRAM-2018


LONDON
UNITED KINGDOM

August 6-8, 2018
Renaissance
London Heathrow
Hotel

GROUND FLOOR

R
RENAISSANCE®
LONDON HEATHROW HOTEL
Bath Road, Hounslow
England
TW6 2AQ

Venue Floor Plan



Wi-Fi Details:
Login – Renaissance_conference
Password – Global2018

Exhibitor



GeneFirst Ltd is a molecular diagnostics company delivering proprietary technologies and products, NGS and PCR, in the fields of cancer diagnostics, infectious disease and personalised medicine. GeneFirst offers robust easy-to-use, sensitive, and affordable products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe, effective and affordable medicines.



DAY 1

CRT-2018 PROGRAM

08:45 Registrations and Welcome Refreshments @ Starbucks
09:15 CRT-2018 Inaugural Address

Keynotes

@ Waterloo Suite

- 09:30** **The Proton Preparation NSC-631570 (UKRAIN) and its Selective Effect**
Techn. Wassil Nowicky, Ukrainian Anti-Cancer Institute, Austria
- 10:00** **Resistance to Tyrosine Kinase-targeted Therapy in Lung Cancer: Autophagy and Metabolic Changes**
Olivier E Pardo, Imperial College, London, United Kingdom
- 10:30** **Role of mTOR in the Tumor Endothelium**
Olivier Dormond, CHUV, Switzerland

11:00 **Coffee Break** @ Millennium Suite

- 11:20** **Pancreatic Cancer Dictates an Inflammatory Mediated Tumorigenesis in the Host Microenvironment**
Myron R Szewczuk, Queen's University, ON, Canada
- 11:50** **Biology of Cell-free Nucleic Acids and their Role in Initiation, Progression and Metastasis of Cancer**
Indraneel (Neel) Mittra, Tata Memorial Centre, MH, India
- 12:20** **Effects of Far-infrared & Terahertz Onnetsu Therapy on Rheumatoid Arthritis and Various Cancers**
Kazuko Tatsumura, Gaia Holistic Health, NY, USA
- 12:50** **YAP1 as a Therapeutic Target: Novel Regulatory Mechanisms in Tumor Angiogenesis**
Chellappan Srikumar, Moffitt Cancer Center & Research Institute, FL, USA

13:20 **Lunch** @ Market Garden Restaurant

- 14:20** **Specimens, Standards, and Signatures: Keys to the Vision of Precision Medicine**
Carolyn Compton, Arizona State University, AZ, USA



- 14:50** **IL-1-activated Signaling Pathways Induce Resistance to Cisplatin through Δ NP63 in Breast Cancer Cells**
 Isaura Meza, CINVESTAV-IPN, Mexico
- 15:20** **Targeting Transcription-associated Cdks is an Effective Strategy to Combat Glioblastoma and Medulloblastoma with Minimal Effect on Primary Neurons**
 Jaya Padmanabhan, H. Lee Moffitt Cancer Center and Research Institute, FL, USA
- 15:50** **Towards Personalized Medicine for Patients with Recurrent Malignant Brain Tumours**
 Ella L. Kim, Johannes Gutenberg University Medical Center, Germany

16:20-17:30 **Posters & Networking** **@ Millennium Suite**



DAY 1

Poster Session (Millennium Suite)

- P-01 Synthesis and Bio-Applications of Luminescent Transition-Metal Complexes**
Haitao Wang, Hong Kong Baptist University, China
- P-02 Prognostic Variables and their Potential Roles in the Development of Autoimmune Thyroid Disorders in Breast Cancer**
Arif Malik, University of Lahore, Pakistan
Muhammad Abdul Basit Ashraf, University of Lahore, Pakistan
Sulayman Waquar, University of Lahore, Pakistan
- P-03 Gestational Trophoblastic Diseases: A Seven-year Observational Study in the City of Duhok – Iraq**
Eleane Ayou, Azadi Teaching Hospital, Iraq
- P-04 Primary Hepatic Perivascular Epithelioid Cell Tumor (PEComa)-Dilemmas in Diagnosis & Treatment**
Aminder Singh, Dayanand Medical College & Hospital, India
- P-05 Is Lymphadenectomy Essential in Early Stage Endometrium Cancer?**
Tijen Atacag, Dr. Suat Günsel Kyrenia University Medical Faculty, Turkey
- P-06 Polyphenols Act Synergistically with Doxorubicin and Etoposide in Leukemia Cell Lines**
Mahbub AA, Umm Al Qura University, King Saudi Arabia
- P-07 Rational Design of a Novel Anti-Angiogenic Antibody Targeting Clec14a**
Mira Kim, Scripps Korea Antibody Institute, South Korea
- P-08 Human Antibodies Targeting the C-Type Lectin Domain of the Tumor Endothelial Cell Marker Clec14a Regulate Angiogenic Properties *in vitro***
Jihye Jang, Scripps Korea Antibody Institute, South Korea
- P-09 Breast Self-examination Knowledge and Practice among Kuwaiti Women**
Maha Al-Sejari, Kuwait University, Kuwait



Symposium

@ Waterloo Suite

Immunotherapy of Cancer: Triumphs and Challenges and the Impact of Immunosenescence

08:55 Symposium Introduction

Chair **Graham Pawelec**

University of Tuebingen Center for Medical Research (ZMF), Germany
Health Sciences North Research Institute, ON, Canada

09:00 Targeting Caspase-8-dependent Apoptosis in Cancer Cells to Enhance Immunotherapy

Thomas Sayers, CIP and Basic Research Program, Leidos Biomedical Research Inc., FNLCR Frederick, Frederick, MD, USA

09:25 Cancer Immune-monitoring; Challenges of Big Data Management

Shahram Kordasti, King's College London, London, UK

09:50 Immunotherapy of Cancer: Triumphs and Challenges and the Impact of Immunosenescence

Graham Pawelec
University of Tuebingen Center for Medical Research (ZMF), Germany
Health Sciences North Research Institute, ON, Canada

10:15 Inactivation of Type I Interferon Pathway as a Critical Determinant of Immune Suppressive Tumor Microenvironment

Serge Y Fuchs, University of Pennsylvania, PA, USA

10:40 Coffee Break

@ Millennium Suite

10:55 Cancer Immunotherapy with Low-level Whole-body Exposures to Ionizing Radiation

Marek K. Janiak, Military Institute of Hygiene and Epidemiology, Poland

11:20 Co-Inhibitory Immune Signaling Generates the Splicing of an Immunophilin which Marks a Tregs Subset Associated with Immunotherapy Response of Melanoma Patients

Maria Fiammetta Romano, University of Naples Federico II, Italy



DAY 2

CRT-2018 PROGRAM

11:45 **Tumour Infiltrating Lymphocyte Therapy; Melanoma and Beyond**
Gray Kueberuwa, University of Manchester, London, UK

12:10 **Synergistic Interaction of Cancer-reductive and Anti-tumor Driven Immunotherapeutic Activity of a New Class of Oxazaphosphorine Cytostatics**
Georg Voelcker, Institute of Biochemistry II, Goethe University Frankfurt Medical School, Frankfurt, Germany

12:35 **Lunch** **@ Market Garden Restaurant**

Notes



Session - Cancer Biology

@ Waterloo Suite

Chairs: Myron R Szewczuk, Queen's University, ON, Canada
 Chellappan Srikumar, Moffitt Cancer Center & Research Institute, FL, USA

13:25 Polyol Pathway as a Novel Therapeutic Target for Aggressive Tumors
 Paolo Ceppi, Uniklinikum Erlangen, IZKF Junior Group 1, Nikolaus-Fiebiger-Zentrum, Germany

13:45 Building Better and Safer NSAIDs: Development and Therapeutic Potential of Hybrids that Release Nitric Oxide and Hydrogen Sulfide
 Khosrow Kashfi, City University of New York School of Medicine, NY, USA

14:05 Selective Anti-cancer Drug NSC631570 Re-educates Alternatively Activated Phagocytes
 Larysa M Skivka, Taras Shevchenko National University of Kyiv, Ukraine

14:25 Therapeutic Resistance in Cancer: Role of Quercetin
 Mukerrem Betul Yerer Aycan, University of Erciyes, Turkey

14:45 Second Generation Proteasome Inhibitors: Side Effects and Potency in Cancer Therapy
 Betul Karademir, School of Medicine, University of Marmara, Turkey

15:05 New Inhibitors of the Tyrosine Kinase ACK1/TNK2 Active in Prostate and Breast Cancer
 Harshani Lawrence, H. Lee Moffitt Cancer Center and Research Institute, FL, USA

15:25 Coffee Break @ Millennium Suite

15:40 Dual Targeting of BET Bromodomains and JAK2 Kinase as a New Anticancer Therapeutic Strategy
 Nicholas J Lawrence, H. Lee Moffitt Cancer Center and Research Institute, FL, USA

16:00 T Cell co-stimulation Vulnerable to Breach by Cancer Cells in the Tumor Microenvironment
 Per thor Straten, University Hospital Herlev, University of Copenhagen, Denmark



DAY 2

CRT-2018 PROGRAM

- 16:20** **Gene Master Regulators and the Personalized Timely Cancer Gene Therapy**
Dumitru A Iacobas, Prairie View A&M University, TX, USA
- 17:00** **Antiangiogenesis in Cancer Therapy – Signaling and Gene Expression Mechanisms of ECM Derived Endogenous Angio-Inhibitor Hexastain and its Sub-Fragment Molecules**
Smita Pawar, Osmania University, TS, India
- 17:20** **Anti-TACE Antibody Drug Development for the Treatment of Cancer**
Hang Fai Kwok, University of Macau, Macau SAR
- 17:40** **Postmastectomy Chest Wall Reirradiation with Proton Therapy for Breast Cancer**
Lisa McGee, Mayo Clinic Arizona, Arizona, USA
- 18:00** **Glutathione is Key to the Synergistic Enhancement of Doxorubicin and Etoposide by Polyphenols in Leukaemia Cell Lines**
Mahbub AA, Umm Al Qura University, King Saudi Arabia

Notes



Session - Types of Cancer & Biomarkers

@ Waterloo Suite

Chairs: Isaura Meza, CINVESTAV-IPN, Mexico

Ella L. Kim, Johannes Gutenberg University Medical Center, Germany

09:00 Metformin Reduces the Risk of Biliary Tract Cancer in Patients with Type 2 Diabetes

Chin-Hsiao Tseng, National Taiwan University College of Medicine, Taiwan

09:20 The Tumour Suppressor OPCML Prevents AXL-mediated EMT and Motility in Ovarian Cancer Cells

Chiara Recchi, Imperial College of London, London, UK

09:40 Aspirin, Oseltamivir Phosphate, and Metformin Sensitize 3D Triple-negative Breast Cancer Spheroids to Tamoxifen Treatment

Nicka Kalaydina, Queen's University, Kingston, ON, Canada

10:00 Association of Ring box-1 Protein Overexpression with Clinicopathologic Prognostic Parameters in Prostate Carcinoma

Zeliha Esin Celik, Selcuk University, Turkey

10:20 Targeting Neuraminidase-1 with Multi-modal Therapy to Sensitize Pancreatic Cancer to Chemotherapy and Moderate the Inflammatory Microenvironment

Bessi Qorri, Queen's University, ON, Canada

10:40 Coffee Break

@ Millennium Suite

11:00 Cancer Vaccines and the Impact of γ -irradiation on the Induction of Bystander Killing by Genetically Engineered Ovarian Tumor Cells: Implications for Clinical Use

Jehad Zweiri, University of Liverpool Medical School, UK

11:20 CDK 4/6 Inhibitors Beyond Estrogen Receptor Positive Breast Cancer: Synergistic Effect of PI3K and CDK4/6 in Triple Negative Breast Cancer

Yuan Yuan, City of Hope, CA, USA



DAY 3

CRT-2018 PROGRAM

11:40 **Biomarker Identification and Neuromodulation as Treatment for Chronic Chemotherapy-induced Peripheral Neuropathy**

Sarah Prinsloo, The University of Texas MD Anderson Cancer Center, TX, USA

12:00 **Clinical Outcomes of Surgical Management for Primary Gastrointestinal Diffuse Large B-cell Lymphoma: At a Single Institution Experience**

Dae Ro Lim, Soonchunhyang University Bucheon Hospital, Korea

12:20- Lunch & Departures @ Market Garden Restaurant



*Meet you again
at
CRT-2019*



UNITED Scientific
Group

8105, Rasor Blvd - Suite #112, PLANO, TX 75024, USA

Ph: +1-408-426-4832, +1-408-426-4833; **Toll Free:** +1-844-395-4102; Fax: +1-408-426-4869

Email: cancer.therapy@uniscigroup.org

Web: www.unitedscientificgroup.com/conferences/cancer-research-therapy